Floatz logo

Aitua Combination Antibody

High-grade Serous Ovarian Cancer (HGSOC)

Cancer Institute and Hospital, Chinese Academy of Medical Sciencesmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

114 Active assets in the High-grade Serous Ovarian Cancer (HGSOC) cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Letrozole
Memorial Sloan Kettering Cancer Center
Phase 3BB
Olaparib
Institute of Cancer Research, United Kingdom
Phase 3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Aitua Combination Antibody is also rated in:

fallopian tube cancerDormant
CCC
Indicative ·
53 / 100
View asset →
primary peritoneal carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →